NCT02077192 2023-12-11
Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
Rigel Pharmaceuticals
Phase 3 Completed
Clinical Trials
9 trialsNCT05393999 2023-04-24
SABRE
Imperial College Healthcare NHS Trust
Phase 2 Withdrawn
NCT01957176 2022-12-30
A Rollover Study to Provide Continued Treatment With Eltrombopag
Novartis
Phase 4 Completed
NCT05328804 2022-04-26
Herombopag + rhTPO in Severe Immune Thrombocytopenia
The First Affiliated Hospital of Soochow University
Phase 3 Unknown
NCT02076399 2019-02-12
FIT
Rigel Pharmaceuticals
Phase 3 Completed
NCT02076412 2019-01-25
FIT
Rigel Pharmaceuticals
Phase 3 Completed
NCT01610180 2018-07-16
Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)
Fondazione Progetto Ematologia
Phase 2 Completed
NCT01444417 2017-02-09
Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients
Amgen
Phase 3 Completed
NCT00515203 2014-07-25
Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects
Amgen
Phase 1/2 Completed